Was the pain worth the gain? Antiretroviral savings from the ‘Improving value’ project and generics use in England

Antiretrovirals (ARVs) have transformed HIV prognosis; most individuals will take treatment lifelong and will enjoy a normal life expectancy. Based on 2015/6 ARV expenditure of £429 million in England, the HIV Clinical Reference Group (CRG) and NHS England (NHSE) developed an improving value (IV)